SG/CALL/MODERNA/190/0.1/17.01.25 | Market Closed - Deutsche Boerse AG 20:47:07 10/05/2024 BST | ||
| 0.45 EUR | -22.41% |
|
| Current month | -2.17% | ||
| 1 month | +4.65% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/05/24 | 0.45 | -22.41% | 0 |
| 09/05/24 | 0.58 | +5.45% | 0 |
| 08/05/24 | 0.55 | +3.77% | 0 |
| 07/05/24 | 0.53 | -7.02% | 0 |
| 06/05/24 | 0.57 | -12.31% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 10, 2024 at 08:47 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SQ860V |
| ISIN | DE000SQ860V4 |
| Date issued | 16/02/2023 |
| Strike | 190 $ |
| Maturity | 17/01/2025 (251 Days) |
| Parity | 10 : 1 |
| Emission price | 4.82 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5 € |
|---|---|
| Lowest since issue | 0.18 € |
| Spread | 0.01 € |
| Spread % | 2.17% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.3
USD
Average target price
139.4
USD
Spread / Average Target
+18.79%
- Stock Market
- Warrants
- Warrant
